您當(dāng)前的位置:檢測資訊 > 監(jiān)管召回
嘉峪檢測網(wǎng) 2025-02-10 20:21
近日,歐盟Eudra GMP數(shù)據(jù)庫更新了一則GMP不符合報告,由比利時聯(lián)邦藥品和健康產(chǎn)品局(Federal Agency For Medicines And Health Products)向 Maithili Life Sciences Private Limited 發(fā)布的不符合GMP聲明(報告編號:BE/NC/2024/01),該報告中披露:由于一些可能導(dǎo)致最終生產(chǎn)的API 污染/交叉污染的主要GMP失敗,并且不能排除對患者安全的風(fēng)險,因此將一般缺陷提出為嚴(yán)重缺陷。
Nature of non-compliance:
不符合情況:
During the inspection, 24 deficiencies against EU GMP were identified. Of these, based on a number of major EU GMP failures that could potentially lead to contamination/cross-contamination of the final APIs produced, and as a risk for the patient’s safety cannot be excluded, a general deficiency was raised as critical. The major GMP failures were observed in the areas of raw materials contamination/degradation and mix-up control, advanced intermediates contamination/cross contamination control, APIs contamination/cross contamination control, design, cleaning and maintenance of equipment, cleaning validation, change control management and quality risk management, deviation management, data integrity and quality control.
在檢查過程中,發(fā)現(xiàn)了 24 項GMP 缺陷。其中,由于一些可能導(dǎo)致最終生產(chǎn)的API 污染/交叉污染的主要GMP失敗,并且不能排除對患者安全的風(fēng)險,因此將一般缺陷提出為嚴(yán)重缺陷。在原料污染/降解和混淆控制、高級中間體污染/交叉污染控制、原藥污染/交叉污染控制、設(shè)備設(shè)計、清潔和維護(hù)、清潔驗證、變更控制管理和質(zhì)量風(fēng)險管理、偏差管理、數(shù)據(jù)完整性和質(zhì)量控制等領(lǐng)域觀察到主要GMP 失敗。
采取措施:
上市許可變更:建議評估是否需要變更上市許可,以刪除或替換該制造商。
召回已放行的批次:如果存在替代供應(yīng)商且無短缺風(fēng)險,應(yīng)評估召回藥品的必要性。
禁止供應(yīng):鑒于不符合 GMP 的性質(zhì),建議禁止供應(yīng),除非沒有替代供應(yīng)商且存在短缺風(fēng)險。
暫停或撤銷 CEP:EDQM 已暫停與 Biperiden Hydrochloride 相關(guān)的 CEP,并關(guān)閉了 Sumatriptan succinate 的申請。

來源:Internet